I I Raad1, A M Chaftari2, M M Al Shuaibi2, Y Jiang2, W Shomali2, J E Cortes3, B Lichtiger4, R Y Hachem2. 1. Departments of Infection Control, Infectious Diseases and Employee Health. Electronic address: iraad@mdanderson.org. 2. Departments of Infection Control, Infectious Diseases and Employee Health. 3. Department of Leukemia. 4. Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
Abstract
BACKGROUND: Granulocyte transfusions (GTXs) have been used successfully as an adjunctive treatment option for invasive infections in some neutropenic patients with underlying hematologic malignancy (HM). PATIENTS AND METHODS: We sought to determine the impact of GTX as an adjunct to antifungal therapy in 128 patients with HM and prolonged neutropenia (≥14 days) with a proven or probable invasive aspergillosis (IA) infection by retrospectively reviewing our institutional database. RESULTS: Fifty-three patients received GTX and 75 did not. By univariate analysis, patients with invasive pulmonary aspergillosis who received GTX were less likely to respond to antifungal therapy (P = 0.03), and more likely to die of IA (P = 0.009) when compared with the non-GTX group. Among patients who received GTX, 53% developed a pulmonary reaction. Furthermore, IA-related death was associated with the number of GTX given (P = 0.018) and the early initiation of GTX within 7 days after starting antifungal therapy (P = 0.001). By multivariate competing risk analysis, patients who received GTX were more likely to die of IA than patients who did not receive GTX (P = 0.011). CONCLUSIONS: Our study suggests that GTX does not improve response to antifungal therapy and is associated with worse outcomes of IA infection in HM patients, particularly those with pulmonary involvement.
BACKGROUND: Granulocyte transfusions (GTXs) have been used successfully as an adjunctive treatment option for invasive infections in some neutropenicpatients with underlying hematologic malignancy (HM). PATIENTS AND METHODS: We sought to determine the impact of GTX as an adjunct to antifungal therapy in 128 patients with HM and prolonged neutropenia (≥14 days) with a proven or probable invasive aspergillosis (IA) infection by retrospectively reviewing our institutional database. RESULTS: Fifty-three patients received GTX and 75 did not. By univariate analysis, patients with invasive pulmonary aspergillosis who received GTX were less likely to respond to antifungal therapy (P = 0.03), and more likely to die of IA (P = 0.009) when compared with the non-GTX group. Among patients who received GTX, 53% developed a pulmonary reaction. Furthermore, IA-related death was associated with the number of GTX given (P = 0.018) and the early initiation of GTX within 7 days after starting antifungal therapy (P = 0.001). By multivariate competing risk analysis, patients who received GTX were more likely to die of IA than patients who did not receive GTX (P = 0.011). CONCLUSIONS: Our study suggests that GTX does not improve response to antifungal therapy and is associated with worse outcomes of IA infection in HM patients, particularly those with pulmonary involvement.
Authors: Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez Journal: N Engl J Med Date: 2007-01-25 Impact factor: 91.245
Authors: B Bielorai; A Toren; B Wolach; M Mandel; H Golan; Y Neumann; C Kaplinisky; M Weintraub; N Keller; N Amariglio; J Paswell; G Rechavi Journal: Bone Marrow Transplant Date: 2000-11 Impact factor: 5.483
Authors: J B Alavi; R K Root; I Djerassi; A E Evans; S J Gluckman; R R MacGregor; D Guerry; A D Schreiber; J M Shaw; P Koch; R A Cooper Journal: N Engl J Med Date: 1977-03-31 Impact factor: 91.245
Authors: M G Seidel; C Peters; A Wacker; H Northoff; R Moog; A Boehme; G Silling; W Grimminger; H Einsele Journal: Bone Marrow Transplant Date: 2008-08-11 Impact factor: 5.483
Authors: Lorenz Grigull; Andreas Beilken; Hansjoerg Schmid; P Kirschner; Karl-Walter Sykora; Christin Linderkamp; Frank Donnerstag; Lilia Goudeva; Hans-Gert Heuft; Karl Welte Journal: Support Care Cancer Date: 2006-02-16 Impact factor: 3.603
Authors: Qi Hui Sam; Wen Shan Yew; Chaminda J Seneviratne; Matthew Wook Chang; Louis Yi Ann Chai Journal: Front Microbiol Date: 2018-07-25 Impact factor: 5.640
Authors: Pinkal M Desai; Janice Brown; Saar Gill; Melham M Solh; Luke P Akard; Jack W Hsu; Celalettin Ustun; Charalambos Andreadis; Olga Frankfurt; James M Foran; John Lister; Gary J Schiller; Matthew J Wieduwilt; John M Pagel; Patrick J Stiff; Delong Liu; Irum Khan; Wendy Stock; Suman Kambhampati; Martin S Tallman; Lawrence Morris; John Edwards; Iskra Pusic; Hagop M Kantarjian; Richard Mamelok; Alicia Wong; Rodney Van Syoc; Lois Kellerman; Swapna Panuganti; Ramkumar Mandalam; Camille N Abboud; Farhad Ravandi Journal: J Clin Oncol Date: 2021-06-22 Impact factor: 50.717